GRAIL Faces Class Action Lawsuit Over Cancer Trial Disclosures
GRAIL, Inc. is under investigation for alleged securities law violations related to its NHS-Galleri cancer screening trial. Investors who suffered losses are invited to participate in a class action lawsuit.
Shareholder rights firm Hagens Berman is investigating GRAIL, Inc. (NASDAQ: GRAL) for alleged violations of U.S. securities laws. The investigation centers on claims that the company misled investors regarding the design and efficacy of its NHS-Galleri cancer screening trial.
The lawsuit alleges that GRAIL repeatedly asserted the trial's adequacy for demonstrating a reduction in late-stage cancer diagnoses within a three-year follow-up period. Investors claim the company concealed internal data suggesting this timeframe was insufficient and selectively released favorable results while withholding critical data.
GRAIL informed investors on February 19, 2026, that the NHS-Galleri trial failed to meet its primary endpoint. The company acknowledged that a longer follow-up period might have been necessary, leading to a significant drop in GRAIL's stock price, approximately 50.55%, and erasing over $2.2 billion in market value.
Hagens Berman is seeking investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, and experienced substantial losses. The deadline for individuals to apply to lead the class action is August 4, 2026. The firm also encourages individuals with relevant information about the trial to contact them.